ACM
DNLI icon

ADAR1 Capital Management’s Denali Therapeutics DNLI Stock Holding History

ADAR1 Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5M Sell
1,029,080
-842,375
-45% -$17.3M 1.21% 14
2026
Q1 		$35.9M Buy
1,871,455
+1,819,339
+3,491% +$36.2M 2.12% 10
2025
Q4 		$860K Buy
52,116
+600
+1% +$10.1K 0.06% 142
2025
Q3 		$748K Buy
51,516
+15,800
+44% +$227K 0.07% 114
2025
Q2 		$500K Buy
35,716
+21,843
+157% +$307K 0.08% 119
2025
Q1 		$189K Sell
13,873
-30,953
-69% -$593K 0.04% 149
2024
Q4 		$914K Sell
44,826
-57,000
-56% -$1.46M 0.18% 86
2024
Q3 		$2.97M Buy
101,826
+63,826
+168% +$1.58M 0.48% 39
2024
Q2 		$882K Buy
38,000
+36,000
+1,800% +$691K 0.17% 71
2024
Q1 		$41K Buy
+2,000
New +$37.6K 0.01% 191

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's DNLI Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Denali Therapeutics (DNLI) stake by 45% in Q2 2026, selling an estimated $17.3M and leaving 1,029,080 shares worth $26.5M. The position accounts for 1.21% of the portfolio, ranked #14.

ADAR1 Capital Management first reported a position in DNLI in Q1 2024 and has held it in 10 quarters since. The position peaked at $35.9M in Q1 2026. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • ADAR1 Capital Management held 1,029,080 shares of Denali Therapeutics worth $26.5M as of Q2 2026.
  • ADAR1 Capital Management sold 842,375 Denali Therapeutics shares in Q2 2026, an estimated $17.3M.
  • Denali Therapeutics made up 1.21% of ADAR1 Capital Management's portfolio in Q2 2026, its #14 holding.
  • ADAR1 Capital Management first reported a position in Denali Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Denali Therapeutics position peaked at $35.9M in Q1 2026.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.